Using chest CT scans and lab data to tell asthma from COPD
Looks at chest CT and biological samples in adults with asthma or COPD.
Plain-language title generated from the registry record
Registry title: Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response
Key facts
- Where
- Seoul, South KoreaSee the 2 sites
Where in South Korea
- Korea University Guro HospitalSeoul, South KoreaTaking people
- SMG-SNU Boramae Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Korea University Guro Hospital
- Trial code
- NCT07602192
- Record updated
- 7 July 2026
- Original description
This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data.Read full original descriptionShow less
Prospective Multicenter Cohort to Discriminate Asthma Versus Chronic Obstructive Pulmonary Disease and Predict Treatment Response Using Quantitative Chest CT and Multi-Omics
This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data.
Adults with asthma or COPD will be enrolled and undergo routine clinical evaluations, pulmonary function tests, blood tests, and chest CT scans. Additional samples, such as sputum and microbiome specimens, may also be collected. No experimental drugs or devices will be administered as part of this study.
Researchers will analyze CT imaging features together with clinical, laboratory, and biological data to better distinguish asthma from COPD and to identify factors that may predict treatment response. The findings are expected to contribute to more precise and personalized management of chronic airway diseases.
Inclusion: Age ≥19 years; COPD group: post-bronchodilator FEV1/FVC < 0.70; Asthma group: clinically confirmed diagnosis of asthma by a physician; Able to provide voluntary written informed consent.
Exclusion: Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks; Inability to undergo chest CT (e.g., poor cooperation or severe medical condition); Pregnancy or breastfeeding; Refusal to consent to study procedures.